Perioperative GLP‑1 Management: What Every Diabetes Team Needs to Know

GLP‑1 receptor agonists and dual agonists like tirzepatide have become indispensable in managing type 2 diabetes and obesity. However, their effect on gastric emptying introduces specific risks during surgery that can’t be ignored. As their use grows, the need for clear, coordinated GLP‑1 perioperative management is more important than ever. This article offers practical guidance, a surgical medication checklist, and key communication strategies that every diabetes care team should follow when preparing a patient for surgery.

Understanding GLP‑1 Agents and Dual Agonists

GLP‑1 receptor agonists such as semaglutide, liraglutide, and exenatide work by enhancing insulin secretion and delaying gastric emptying. Tirzepatide, a dual GIP/GLP‑1 agonist, has a similar profile with added glycemic benefits. These pharmacological effects improve metabolic control but complicate perioperative management, especially for patients undergoing sedation or general anesthesia. Delayed gastric emptying can increase aspiration risk. Anesthesia teams rely on an empty stomach to reduce intraoperative complications, which makes the preoperative hold of these agents crucial. Most importantly, medication half-life varies—weekly agents like semaglutide linger in the system longer, requiring a longer pause before surgery than shorter-acting options.

Why Perioperative Management Matters

Perioperative glucose control is critical to prevent both hyperglycemia and hypoglycemia, both of which can impair healing and increase postoperative complications. GLP‑1 agents present additional challenges due to slowed gastric motility, which increases the chance of retained stomach contents during anesthesia induction. Patients may also experience persistent nausea postoperatively, making medication resumption and oral intake planning even more vital. Without a well-coordinated perioperative plan, the very medications that offer long-term health benefits may become acute surgical risks.

Updated Perioperative Guidance

Recent guidelines recommend that GLP‑1 agents be held prior to surgery, though timing varies: Short-acting GLP‑1 RAs (like exenatide BID): hold 24 hours before surgery. Long-acting GLP‑1 RAs (like semaglutide or tirzepatide): hold for 1 to 2 weeks before surgery, depending on the procedure type and risk level. In urgent or emergent procedures, anesthesia teams may use ultrasound or other tools to assess gastric contents when there’s concern about delayed emptying. For elective surgeries, holding medication in advance remains the safest approach.

Practical Perioperative Checklist

A standardized perioperative checklist ensures safety and consistency across care teams. Here’s a template you can customize: Review the patient’s GLP‑1 or dual agonist name, dose, and schedule. Determine the appropriate medication hold window based on type. Align anesthesia fasting orders with known gastric motility delays. Prepare an alternative glucose management plan (often insulin-based). Educate the patient on when to resume therapy postoperatively. Confirm tolerance of oral intake before restarting GLP‑1 medications. This checklist should be integrated into the EHR or pre-op surgical workflow to ensure all teams stay aligned.

Optimizing Team Communication

Siloed decision-making increases risk. That’s why multidisciplinary collaboration is essential. The diabetes care team, surgical providers, and anesthesia group should coordinate perioperative plans early in the preoperative process. Key communication practices include: Shared EHR notes outlining medication holds and glucose targets. Clear patient instructions that prevent confusion or non-adherence. Preoperative huddles for high-risk cases to confirm fasting status and alternative glucose plans. Ultimately, clear roles and early collaboration reduce confusion and improve patient safety during the perioperative period.

Conclusion

GLP‑1 perioperative management is more than just a medication hold—it’s a coordinated effort that blends pharmacology, surgical timing, and patient education. Diabetes care teams who understand how to navigate GLP‑1 therapy in the surgical setting will not only reduce complications but also enhance long-term outcomes for their patients. With practical checklists and interdisciplinary communication, perioperative planning becomes safer, smarter, and more streamlined.

Frequently Asked Questions

How long before surgery should GLP‑1 medications be stopped?

Timing depends on the drug. Short-acting agents are typically held 24 hours prior, while long-acting agents may be held for 7–14 days before surgery.

Can GLP‑1 medications be resumed soon after surgery?

Yes, but only after the patient can tolerate oral intake without nausea and glucose levels are stable.

Why is delayed gastric emptying a concern during anesthesia?

Because it raises the risk of aspiration during induction. An empty stomach reduces that risk, which is why medication timing and fasting alignment are critical.

What if surgery is urgent and GLP‑1 medications were not held?

In urgent cases, anesthesia may assess gastric content using ultrasound and proceed with extra caution or alternative techniques.

Where can I find more detailed guidance?

The American Diabetes Association and perioperative management resources offer updated protocols. You can also visit DiabetesInControl.com for more insights.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.